Biogen Inc
NASDAQ:BIIB

  • LAST PRICE
    160.7300
  • TODAY'S CHANGE (%)
    -4.1600 (-2.5229%)
  • Bid / Lots
    160.5300/ 7
  • Ask / Lots
    160.7800/ 7
  • Open / Previous Close
    165.4600 / 164.8900
  • Day Range
    159.6800
    166.3400
  • 52 Week Range
    159.6800
    268.2950
  • Volume
    861,788

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BIIB
Biogen Inc
24.0B
14.5x
-18.14%
ICLR
ICON PLC
16.5B
21.2x
+4.68%
MRNA
Moderna Inc
15.3B
-6.4x
---
GRFS
Grifols SA
7.6B
40.8x
---
BNTX
Biontech SE
24.8B
-48.4x
---
IQV
IQVIA Holdings Inc
36.9B
25.2x
+46.62%
As of 2024-11-15

Company Information

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Contact Information

Headquarters
225 Binney StreetCAMBRIDGE, MA, United States 02142
Phone
781-464-2000
Fax
302-636-5454

Executives

Independent Chairman of the Board
Caroline Dorsa
President, Chief Executive Officer, Director
Christopher Viehbacher
Chief Financial Officer, Executive Vice President
Michael McDonnell
Chief Human Resource Officer, Executive Vice President
Ginger Gregory
Executive Vice President, Chief Legal Officer
Susan Alexander

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$24.0B
Revenue (TTM)
$9.6B
Shares Outstanding
145.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.07
EPS
$11.07
Book Value
$102.14
P/E Ratio
14.5x
Price/Sales (TTM)
2.5
Price/Cash Flow (TTM)
10.6x
Operating Margin
22.56%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.